Reference

A selected ion monitoring GC/MS assay for 3,4,4'-trichlorocarbanilide and its metabolites in biological fluids

A selected ion monitoring GC/MS assay for 3,4,4'-trichlorocarbanilide and its metabolites in biological fluids. Gruenke, Larry D.; Craig, John C.In this study， 62950-30-5 and 67200-81-1 are also used.; Wester, Ronald C.; Maibach, Howard I.; North-Root, Helen; Corbin, Neal C. (Sch. Pharm., Univ. California, San Francisco, CA 94143, USA). J. Anal. Toxicol., 11(2), 75-80 (English) 1987. CODEN: JATOD3. ISSN: 0146-4760. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 62 A selected ion monitoring gas chromatog./mass spectrometric (GC/MS) method for the quant. detn. of 3,4,4'-trichlorocarbanilide (I) [101-20-2] and its major metabolites (the 2'-hydroxysulfate [62950-30-5] and the N- [67200-80-0] and N'-glucuronide [67200-81-1]) in human plasma and urine was developed using the deuterium-labeled compds. as internal stds. Limits of detection of 3 ng/mL in urine for the N-glucuronides and of 1.5 ng/mL in plasma for the 2'-hydroxy sulfate were attained. Use of the method was illustrated in a study in human subjects employing I-contg. bar soaps. .

Metabolism and toxicity of halogenated carbanilides: absorption, distribution and excretion of radioactivity from 3,4,4'-trichloro[14C]-carbanilide (TCC) and 3-trifluoromethyl-4,4'-dichloro[14C]-carbanilide (TFC) in rats

Metabolism and toxicity of halogenated carbanilides: absorption, distribution and excretion of radioactivity from 3,4,4'-trichloro[14C]-carbanilide (TCC) and 3-trifluoromethyl-4,4'-dichloro[14C]-carbanilide (TFC) in rats. Hiles, R. A. (Miami Val. Lab., Procter and Gamble Co., Cincinnati, Ohio, USA). Food Cosmet. Toxicol., 15(3), 205-11 (English) 1977. CODEN: FCTXAV. DOCUMENT TYPE: Journal CA Section: 4 (Toxicology) The absorption, distribution and excretion of 14C-labeled TCC (I) [101-20-2] and TFC (II) [369-77-7] were evaluated in rats given a single oral, i.v. or dermal dose of radioactive material. With either compd. and with each route of administration, >65% of the absorbed radioactivity was eliminated in the bile during the 72 h after dosing. The organ distribution at 72 h was liver >kidneys .mchgt.lungs .simeq.testes, with the liver contg. <1% of the absorbed dose. There were enough similarities between i.v., oral and dermal exposure with respect to elimination routes and tissue distribution to justify the conclusion that oral exposure could be used in toxicity evaluations and still be relevant to dermal exposure. Enterohepatic circulation was evaluated using rats with bile ducts cannulated in tandem. Between 30 and 60% of the material eliminated into the gastrointestinal tract was reabsorbed. The tissue distribution and the relative contribution of the bile and urine to elimination of this reabsorbed radioactivity was very similar to that found in rats given an oral dose of radioactive I or II. Both I and II are probably extensively metabolized, but evidence was obtained showing that cleavage of the C-N bond is not involved to a detectable extent.